DNM1L and cancer: On this basis, the selective antagonism of mitochondrial fission via Drp1 targeting might represent a promising therapeutic approach for cancer, and Drp1 synthetic inhibitors have proven effective in reducing proliferation and inducing apoptosis in cancer cells, both in vitro and in vivo [61, 62].